These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 38128180)
1. Integrated transcriptomic and proteomic analysis reveals Guizhi-Fuling Wan inhibiting STAT3-EMT in ovarian cancer progression. Ma Q; Chen F; Liu Y; Wu K; Bu Z; Qiu C; Neamati N; Lu T Biomed Pharmacother; 2024 Jan; 170():116016. PubMed ID: 38128180 [TBL] [Abstract][Full Text] [Related]
2. Guizhi Fuling capsule relieves memory deficits by inhibition of microglial neuroinflammation through blocking JAK2/STAT3 pathway in presenilin1/2 conditional double knockout mice. Yang G; Tong Y; Wang X; Zhao C; Ba Z; Ahelijiang R; Liu X; Gao W; Zhao Y; Gu Y; Yang J; Xu Y Front Immunol; 2023; 14():1185570. PubMed ID: 37465679 [TBL] [Abstract][Full Text] [Related]
3. Protective mechanism of traditional Chinese medicine guizhi fuling pills against carbon tetrachloride-induced kidney damage is through inhibiting oxidative stress, inflammation and regulating the intestinal flora. Xu B; Zheng J; Tian X; Yuan F; Liu Z; Zhou Y; Yang Z; Ding X Phytomedicine; 2022 Jul; 101():154129. PubMed ID: 35490491 [TBL] [Abstract][Full Text] [Related]
4. Guizhi fuling capsule, an ancient Chinese formula, attenuates endometriosis in rats via induction of apoptosis. Hu C; Wang Z; Pang Z; Lu W; Cai X; Yang J; Wang D; Cao P Climacteric; 2014 Aug; 17(4):410-6. PubMed ID: 24559203 [TBL] [Abstract][Full Text] [Related]
5. Systemic pharmacological verification of Guizhi Fuling decoction in treating endometriosis-associated pain. Gao Y; Ji W; Lu M; Wang Z; Jia X; Wang D; Cao P; Hu C; Sun X; Wang Z J Ethnopharmacol; 2022 Oct; 297():115540. PubMed ID: 35870685 [TBL] [Abstract][Full Text] [Related]
6. Guizhi Fuling pill attenuates liver fibrosis Liu Z; Xu B; Ding Y; Ding X; Yang Z Bioengineered; 2022 Apr; 13(4):9357-9368. PubMed ID: 35387552 [TBL] [Abstract][Full Text] [Related]
7. The anti-cancer mechanism of Celastrol by targeting JAK2/STAT3 signaling pathway in gastric and ovarian cancer. Wu K; Qiu C; Ma Q; Chen F; Lu T Toxicol Appl Pharmacol; 2024 Oct; 491():117077. PubMed ID: 39181414 [TBL] [Abstract][Full Text] [Related]
8. Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3. Lu T; Bankhead A; Ljungman M; Neamati N Theranostics; 2019; 9(19):5478-5496. PubMed ID: 31534498 [TBL] [Abstract][Full Text] [Related]
9. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis. Yuan S; Xu Y; Yi T; Wang H J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446 [TBL] [Abstract][Full Text] [Related]
10. Integrated Metabolomics and Network Pharmacology to Reveal the Mechanisms of Guizhi-Fuling Treatment for Myocardial Ischemia. Duan B; Ye Y; Zhou Z; Han L; Huang F; Li J; Wang Q; Zeng X; Yu X Chem Biodivers; 2022 Oct; 19(10):e202200386. PubMed ID: 36073658 [TBL] [Abstract][Full Text] [Related]
11. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib. Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601 [TBL] [Abstract][Full Text] [Related]
12. Ginkgetin suppresses ovarian cancer growth through inhibition of JAK2/STAT3 and MAPKs signaling pathways. Wu L; Qian C; Zhang W; Shi M; Chen X; Wang Y; Lin F Phytomedicine; 2023 Jul; 116():154846. PubMed ID: 37172479 [TBL] [Abstract][Full Text] [Related]
13. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling. Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049 [TBL] [Abstract][Full Text] [Related]
14. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391 [TBL] [Abstract][Full Text] [Related]
15. Serotonin/HTR1E signaling blocks chronic stress-promoted progression of ovarian cancer. Qin X; Li J; Wang S; Lv J; Luan F; Liu Y; Chen Y; Chen X; Zhao Y; Zhu J; Piao Y; Zhang W; Shi Y; Xiang R; Qu P; Wang L Theranostics; 2021; 11(14):6950-6965. PubMed ID: 34093864 [No Abstract] [Full Text] [Related]
16. L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling. Giordano M; Decio A; Battistini C; Baronio M; Bianchi F; Villa A; Bertalot G; Freddi S; Lupia M; Jodice MG; Ubezio P; Colombo N; Giavazzi R; Cavallaro U J Exp Clin Cancer Res; 2021 Oct; 40(1):319. PubMed ID: 34645505 [TBL] [Abstract][Full Text] [Related]
17. MiR-3666 serves as a tumor suppressor in ovarian carcinoma by down-regulating AK4 via targeting STAT3. Tan H; Wu C; Huang B; Jin L; Jiang X Cancer Biomark; 2021; 30(4):355-363. PubMed ID: 33361582 [TBL] [Abstract][Full Text] [Related]
18. Add-on effect of the Guizhi Fuling formula for management of reduced fertility potential in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Rong A; Ta N; E L; Meng W Front Endocrinol (Lausanne); 2022; 13():995106. PubMed ID: 37143960 [TBL] [Abstract][Full Text] [Related]
19. A Chinese classical prescription Guizhi-Fuling Wan in treatment of ovarian cancer: An overview. Wang X; Su P; Hao Q; Zhang X; Xia L; Zhang Y Biomed Pharmacother; 2022 Sep; 153():113401. PubMed ID: 36076526 [TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of Chinese herbal medicine Guizhi Fuling capsule combined with low dose mifepristone in the treatment of uterine fibroids: a systematic review and meta-analysis of 28 randomized controlled trials. Lei Y; Yang L; Yang H; Li M; Ou L; Bai Y; Dong T; Gao F; Wei P BMC Complement Med Ther; 2023 Feb; 23(1):54. PubMed ID: 36803997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]